Carlyle
Latest statistics and disclosures from Carlyle Group's latest quarterly 13F-HR filing:
- Top 5 stock holdings are QDEL, ZI, SLNO, VTRU, VRNA, and represent 83.50% of Carlyle Group's stock portfolio.
- Added to shares of these 10 stocks: SLNO (+$52M), JSPR (+$31M), Q32 Bio (+$18M), DNUT (+$5.2M), Effector Therapeutics, ACET, NABL, CSLR, SWI, AVGO.
- Started 10 new stock positions in JSPR, Effector Therapeutics, NU, SWI, DASH, CFLT, AVGO, NABL, Q32 Bio, DNUT.
- Reduced shares in these 5 stocks: ZI (-$144M), VERA (-$22M), Jasper Therapeutics (-$6.7M), Effector Therapeutics, GETY.
- Sold out of its positions in Effector Therapeutics, Jasper Therapeutics, VERA.
- Carlyle Group was a net seller of stock by $-59M.
- Carlyle Group has $1.6B in assets under management (AUM), dropping by -23.71%.
- Central Index Key (CIK): 0001527166
Tip: Access up to 7 years of quarterly data
Positions held by Carlyle consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Carlyle Group
Carlyle Group holds 32 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Quidel Corp (QDEL) | 37.7 | $597M | 13M | 47.94 |
|
|
| ZoomInfo Technologies Common Stock (ZI) | 26.5 | $421M | -25% | 26M | 16.03 |
|
| Soleno Therapeutics (SLNO) | 10.9 | $173M | +42% | 4.1M | 42.52 |
|
| Vitru Ord (VTRU) | 5.9 | $94M | 6.2M | 15.05 |
|
|
| Verona Pharma Sponsored Ads (VRNA) | 2.5 | $39M | 2.5M | 16.05 |
|
|
| Getty Images Holdings Cl A Com (GETY) | 2.4 | $38M | 9.2M | 4.15 |
|
|
| Phathom Pharmaceuticals (PHAT) | 2.3 | $37M | 3.5M | 10.61 |
|
|
| Jasper Therapeutics Com New (JSPR) | 2.0 | $31M | NEW | 1.1M | 29.36 |
|
| Hillevax (HLVX) | 1.9 | $31M | 1.8M | 16.59 |
|
|
| GDS Hldgs Sponsored Ads (GDS) | 1.7 | $27M | 4.1M | 6.65 |
|
|
| Seacor Marine Hldgs (SMHI) | 1.2 | $18M | 1.3M | 13.94 |
|
|
| Q32 Bio | 1.1 | $18M | NEW | 1.1M | 16.39 |
|
| Invitation Homes (INVH) | 1.1 | $17M | 478k | 35.61 |
|
|
| Cubesmart (CUBE) | 0.6 | $10M | 221k | 45.22 |
|
|
| Adicet Bio (ACET) | 0.4 | $6.9M | +39% | 2.9M | 2.34 |
|
| Krispy Kreme (DNUT) | 0.3 | $5.2M | NEW | 341k | 15.23 |
|
| Reneo Pharmaceuticals (RPHM) | 0.3 | $4.5M | 2.7M | 1.65 |
|
|
| Smart Sh Global Ads (EM) | 0.2 | $3.2M | 4.8M | 0.66 |
|
|
| Effector Therapeutics Com New | 0.2 | $2.7M | NEW | 193k | 14.11 |
|
| Complete Solaria (CSLR) | 0.2 | $2.7M | +79% | 4.9M | 0.55 |
|
| Spruce Biosciences (SPRB) | 0.1 | $2.3M | 2.9M | 0.79 |
|
|
| N-able Common Stock (NABL) | 0.1 | $1.2M | NEW | 94k | 13.07 |
|
| Solarwinds Corp Com New (SWI) | 0.1 | $1.2M | NEW | 94k | 12.62 |
|
| Broadcom (AVGO) | 0.1 | $1.0M | NEW | 755.00 | 1325.25 |
|
| Nu Hldgs Ord Shs Cl A (NU) | 0.1 | $863k | NEW | 72k | 11.93 |
|
| Nucana Sponsored Adr (NCNA) | 0.1 | $845k | 3.3M | 0.25 |
|
|
| DoorDash Cl A (DASH) | 0.0 | $572k | NEW | 4.2k | 137.72 |
|
| Spyre Therapeutics Com New (SYRE) | 0.0 | $365k | 9.6k | 37.92 |
|
|
| Meta Data Sponsored Ads (AIU) | 0.0 | $241k | 314k | 0.77 |
|
|
| Confluent Class A Com (CFLT) | 0.0 | $235k | NEW | 7.7k | 30.52 |
|
| Exicure Com New (XCUR) | 0.0 | $161k | 282k | 0.57 |
|
|
| Molecular Templates Com New (MTEM) | 0.0 | $29k | 13k | 2.15 |
|
Past Filings by Carlyle Group
SEC 13F filings are viewable for Carlyle Group going back to 2012
- Carlyle Group 2024 Q1 filed May 3, 2024
- Carlyle Group 2023 Q4 filed Feb. 2, 2024
- Carlyle Group 2023 Q3 filed Nov. 3, 2023
- Carlyle Group 2023 Q2 filed Aug. 4, 2023
- Carlyle Group 2023 Q1 filed May 5, 2023
- Carlyle Group 2022 Q4 filed Feb. 10, 2023
- Carlyle Group 2022 Q3 filed Nov. 10, 2022
- Carlyle Group 2022 Q2 filed Aug. 12, 2022
- Carlyle Group 2022 Q1 filed May 13, 2022
- Carlyle Group 2021 Q4 filed Feb. 11, 2022
- Carlyle Group 2021 Q3 filed Nov. 12, 2021
- Carlyle Group 2021 Q2 filed Aug. 12, 2021
- Carlyle Group 2021 Q1 filed May 14, 2021
- Carlyle Group 2020 Q4 filed Feb. 12, 2021
- Carlyle Group 2020 Q3 filed Nov. 13, 2020
- Carlyle Group 2020 Q2 filed Aug. 13, 2020